Siponimod granted European licence for active secondary progressive MS
The European Commission has granted marketing authorization for siponimod (Mayzent) for active secondary progressive MS. This follows a recommendation from the European Medicines Agency that a licence should be granted.
- Active secondary progressive MS is defined as people experiencing relapses or showing signs of inflammation in MRI scans.
Siponimod will now need to be assessed by NICE and the SMC to decide NHS availability in the UK. NICE has started the process with a decision due to be published in May this year. SMC has also scheduled an appraisal, with the decision published in July. The MS Trust is contributing to both appraisals. If the appraisals are successful, siponimod could potentially be available as an NHS treatment from September this year.
About siponimod
Siponimod is taken as a tablet, once a day.
In clinical trials for secondary progressive MS, siponimod reduced the risk of disability progression by 26% compared to placebo. Further analysis indicated a 37% reduction in the risk of progression for those with active SPMS (defined as those who had relapsed in the two years prior to starting the trial).
In clinical trials, low white blood cell count, increased liver enzyme levels, slower heart rate when starting treatment, macular oedema (swelling in the back of the eye affecting vision), high blood pressure, shingles, and convulsions occurred more frequently with siponimod than with placebo.
Find out more
- Siponomid
- Novartis press release
- NICE - appraisal of siponimod
- SMC - appraisal of siponimod
- Secondary progressive MS
- Secondary progressive MS - order or download MS Trust book


Updated NICE multiple sclerosis guideline contains some good news and some bad news
22/06/2022 - 00:00
There are some positive points in the revised 2022 guideline but the MS Trust is disappointed that NICE has been unable to recommend Fampyra.


The ADAMS project
25/05/2022 - 00:00
Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.


Is a ketogenic diet good for people with multiple sclerosis?
18/05/2022 - 00:00
Researchers assessed whether a ketogenic diet, low in carbohydrates and high in fats, is suitable for people with multiple sclerosis.


Updated NICE multiple sclerosis guideline contains some good news and some bad news
22/06/2022 - 00:00
There are some positive points in the revised 2022 guideline but the MS Trust is disappointed that NICE has been unable to recommend Fampyra.


Connors letter to MS
21/06/2022 - 00:00
In 2022, Connor will be taking part in the Great North Run to support the MS Trust. Here, Connor writes a letter to MS, openly sharing his thoughts on the condition his sister was diagnosed with at the age of 14.


Why is Pride month important to the MS Trust?
16/06/2022 - 00:00
As part of our Pride month celebrations, two of the MS Trust team who identify as members of the LGBTQ+ community, sat down with David Martin, the MS Trust’s CEO, to discuss the importance of celebrating the LGBTQ+ community - not just in June but throughout the year.

Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.